by Kall Kwik WGC | Jan 8, 2018 | Free Library
December, 2017 SMM-171 Amazon’s invasion It’s no good being alarmed about Amazon entering the pharma market as a new channel. The organisation is incredibly competitive; and the disruption it has caused in every market it has touched...
by Kall Kwik WGC | Jan 8, 2018 | Free Library
March, 2017 SMM-158b Choices, choices Not all innovative business models are equal – different ‘species’ of business model are required to fit different parts of the healthcare environment.
by Kall Kwik WGC | Nov 14, 2017 | Free Library
November, 2017 SMM-170 The Great Schism While recent approval by the FDA of Novartis’ new Kymriah gene therapy for leukaemia is undoubtedly cause for celebration, evolution suggests that such technological advance might also be the herald of...
by Kall Kwik WGC | Nov 1, 2017 | Free Library
October, 2017 SMM-169 Pharma’s Coral Reef A comparison of the life science industry past and present reveals that holobionts are now the principal form of competitor, while the fully integrated, self-sufficient company is becoming a...
by Kall Kwik WGC | Nov 1, 2017 | Free Library
October, 2017 SMM-168 Breathing Data Amidst announcements and industry gossip about how companies such as Apple and Google are planning to upend the life science industry by their use of data, Novartis’s new CEO designate, Vas Narasimham,...
by Kall Kwik WGC | Oct 17, 2017 | Free Library
October, 2017 SMM-167 Life Lessons Generics were once an unstoppable behemoth, threatening to dominate the industry as they sucked up market share. But their model seems to be fading. In this low-cost, non-innovative habitat, existing giants are...
